Phreesia Stock Price, News & Analysis

Phreesia (NYSE: PHR) announced that Megan Turco, Director of Client Experience for Phreesia Network Solutions, was named to MM+M’s 2025 40 Under 40. Since joining in 2018, Turco advanced through five roles and scaled the Client Experience team from four people to more than 50. She leads a sales organization servicing 80+ life sciences and agency clients and has overseen programs that reached millions of patients.

The team exceeded targets for four consecutive years with double‑digit annual revenue growth, and internal surveys show 95% client ratings of very good/excellent and 94% reporting great service.

Phreesia (NASDAQ: PHR) was named to the 2025 Deloitte Technology Fast 500, which ranks the 500 fastest-growing tech, media, telecom, life sciences, fintech and energy tech companies in North America based on fiscal year revenue growth from 2021 to 2024. Phreesia said this is its first Fast 500 appearance and credited the recognition to team performance and its mission to simplify care. The release notes eligibility criteria for the list, including base-year revenues of at least $50,000, current-year revenues of at least $5 million, and a minimum four-year operating history. Phreesia reported it enabled approximately 170 million patient visits in 2024 (about 1 in 7 U.S. visits).

Phreesia (NYSE: PHR) will release its fiscal third quarter 2026 results after market close on Monday, Dec. 8, 2025. The company will post a press release and a quarterly stakeholder letter on its investor website at ir.phreesia.com.

Phreesia will host a live conference call and webcast on Dec. 8, 2025 at 5:00 PM Eastern; dial-in numbers and conference code are provided on the investor events page. A replay will be available on the same web link for approximately 90 days.

About Phreesia: a patient-activation platform that enabled approximately 170 million patient visits in 2024, serving healthcare providers and life sciences customers. For investor or media inquiries, contact details are listed on the company site.

Phreesia (NYSE: PHR) was named to the 2025 Capterra Shortlists in the Appointment Reminder and Appointment Scheduling categories on October 8, 2025.

This marks Phreesia's third and fourth shortlist placements in 2025 after earlier inclusion for Patient Engagement and Medical Scheduling. Phreesia reported an overall 4.3/5 rating on Capterra, and highlighted user feedback on reduced no-shows and fewer scheduling calls. The company said its digital tools support provider scheduling, patient engagement and outreach.

Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024, and provides patient intake and digital engagement solutions for healthcare organizations.

Phreesia (NYSE:PHR), a leading patient intake and activation platform, has been recognized on TIME's inaugural World's Top HealthTech Companies of 2025 list. The company received a 'very high' performance indicator in the Health Information & Management category. Phreesia's platform facilitated 170 million patient visits in 2024, representing approximately 1 in 7 healthcare visits across the United States.

The TIME recognition, developed in partnership with Statista, evaluates companies based on financial performance, reputation analysis, and online engagement across six market segments. Phreesia's digital solutions focus on patient intake, outreach, education, and activation, aiming to enhance patient experience and improve healthcare outcomes.

Phreesia (NYSE:PHR), a leading patient intake and activation platform, announced that Sara DiNardo, Vice President of Client Solutions, has been named to Becker's Hospital Review's 2025 Rising Stars: 100 Healthcare Leaders Under 40 list.

DiNardo oversees Phreesia's client-facing teams, focusing on implementing digital tools for healthcare organizations to improve efficiency and patient engagement. During her 10-year tenure at Phreesia, she has become instrumental in helping healthcare clients navigate operational challenges. The company notably facilitated approximately 170 million patient visits in 2024, representing 1 in 7 visits across the United States.

Phreesia (NYSE: PHR) reported strong Q2 fiscal 2026 results, marking its first-ever net income positive quarter. The company achieved total revenue of $117.3 million, up 15% year-over-year, with 4,467 healthcare services clients. Key financial highlights include net income of $0.7 million, compared to a $18.0 million loss last year, and Adjusted EBITDA of $22.1 million, up from $6.5 million.

Phreesia announced a definitive agreement to acquire AccessOne, a healthcare receivables financing solutions provider, expected to close in Q3 or early Q4 FY2026. The company maintained its FY2026 revenue outlook of $472-482 million and raised its Adjusted EBITDA guidance to $87-92 million. The acquisition will be financed through cash and a bridge loan.

Phreesia (NYSE: PHR) has announced a definitive agreement to acquire AccessOne for $160 million in cash. AccessOne, a portfolio company of Frontier Growth, is a market leader in healthcare receivables financing solutions, managing a portfolio of approximately $450 million.

The transaction is expected to close during Q3 or early Q4 of Phreesia's fiscal year 2026. The acquisition will be financed through a combination of cash and a new bridge loan. Phreesia anticipates the acquisition to contribute approximately $35 million in annualized revenue and $11 million in annualized Adjusted EBITDA.

AccessOne's platform provides healthcare providers with scalable, compliant tools for improving collections while maintaining patient trust. The acquisition aligns with Phreesia's mission of making healthcare more accessible and is expected to expand their addressable market.

Phreesia (NYSE:PHR) has launched VoiceAI, an innovative AI-powered phone solution designed specifically for healthcare organizations. This new technology integrates with Phreesia's existing patient activation platform to manage high call volumes and streamline patient interactions using natural language processing.

The system features intelligent triage, reliable AI responses based on clinical rules, parallel call handling capacity, and integrated documentation capabilities. VoiceAI handles common healthcare requests including scheduling, prescription refills, and clinical questions 24/7. Early implementation at Urology Associates of Mobile has already demonstrated success, reducing call abandonment rates to zero.

In 2024, Phreesia facilitated approximately 170 million patient visits, representing 1 in 7 healthcare visits across the United States.